Ferrer Obtains the Distribution Rights for Treprostinil Inhalation Solution Including the Potential Indications for Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF)

Contributed by: Business Wire

Logo

Tags

Medical Devices

Other Health

Health

Pharmaceutical

Clinical Trials

Tyvaso®

More Like This

Pulmonary Hypertension Awareness Month: Two European Studies Highlight the Urgency of Patients and Experts to Improve the Diagnosis and Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease

PR Newswire associated0

Daewoong Pharmaceutical's Bersiporocin Receives 'Orphan Drug Designation' in Europe to Treat Idiopathic Pulmonary Fibrosis

David Ferrando, Ferrer's Chief Marketing and Market Access Officer and Jorge Cuneo, Ferrer's Chief Medical Officer, at the IMPAHCT opening session.

Experts Set International and Multidisciplinary Collaboration As Priorities in Pulmonary Hypertension Management

Novotech Identifies Strategic Opportunities in Idiopathic Pulmonary Fibrosis Trials with Release of Global Market Insights

Chiesi and Gossamer Bio Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in Pulmonary Arterial Hypertension and Other Respiratory Indications

Alentis Receives FDA Orphan Drug Designation for Lixudebart to Treat Idiopathic Pulmonary Fibrosis

Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine

Ferrer Advances Research into Progressive Supranuclear Palsy (PSP) with the Inclusion of the First Participant in a Phase II Clinical Trial